Apogee Therapeutics, Inc. Common Stock
Veridion Score
Composite trend over time
Why is APGE moving today?
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for APGE.
APGE insider activity
Apogee Therapeutics, Inc. Common Stock
2 insiders bought in the last 90 days
Net selling: -$154.8M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-02 | 2026-07-01 | Dambkowski Carl | Insider | sell | $132.74 | 5,500 | 177,873 | $730K | SEC Form 4 |
| 2026-07-02 | 2026-07-01 | Dambkowski Carl | Insider | buy | $22.86 | 4,125 | 183,373 | $94K | SEC Form 4 |
| 2026-06-24 | 2026-06-22 | Dambkowski Carl | Insider | sell | $132.60 | 26,400 | 179,248 | $3.5M | SEC Form 4 |
| 2026-06-24 | 2026-06-22 | HENDERSON MICHAEL THOMAS | Insider | sell | $132.54 | 80,000 | 1,015,987 | $10.6M | SEC Form 4 |
| 2026-06-12 | 2026-06-10 | HENDERSON MICHAEL THOMAS | Insider | sell | $86.89 | 614 | 1,095,987 | $53K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 90 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moAPGE contract awards, year to date.
Public federal awards linked to this ticker.
APGE lobbying filings, year to date.
Registered lobbying filings matched to Apogee Therapeutics, Inc. Common Stock.